Century Therapeutics Inc (IPSC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Century Therapeutics Inc (IPSC) has a cash flow conversion efficiency ratio of -0.085x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.85 Million) by net assets ($232.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see IPSC market cap overview for the company's overall valuation and market capitalisation.
Century Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Century Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Century Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Century Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Century Therapeutics Inc (IPSC) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EuroHold Bulgaria AD
WAR:EHG
|
0.020x |
|
AMTD Digital Inc.
NYSE:HKD
|
0.018x |
|
Unggul Indah Cahaya Tbk
JK:UNIC
|
0.088x |
|
Energy One Ltd
AU:EOL
|
0.115x |
|
Nanjing OLO Home Furnishing
SHG:603326
|
0.055x |
|
BRASI.CIA BRAS.D.PROP.ADR
F:52BA
|
-0.023x |
|
Dadelo S.A.
WAR:DAD
|
0.186x |
|
Bakkt Holdings Inc
NYSE:BKKT
|
-0.071x |
Annual Cash Flow Conversion Efficiency for Century Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Century Therapeutics Inc from 2015 to 2025. View IPSC live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $158.94 Million | $-103.88 Million | -0.654x | +4.24% |
| 2024-12-31 | $161.36 Million | $-110.14 Million | -0.683x | -42.73% |
| 2023-12-31 | $184.75 Million | $-88.35 Million | -0.478x | -1130.25% |
| 2022-12-31 | $302.74 Million | $14.05 Million | 0.046x | +120.66% |
| 2021-12-31 | $396.24 Million | $-89.00 Million | -0.225x | -157.92% |
| 2020-12-31 | $-106.41 Million | $-41.27 Million | 0.388x | +120.34% |
| 2019-12-31 | $-91.86 Million | $-16.17 Million | 0.176x | -39.30% |
| 2015-12-31 | $359.71 Million | $104.30 Million | 0.290x | -- |
About Century Therapeutics Inc
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the deve… Read more